Senores Pharmaceuticals · NSE: SENORES · BSE: 544319
Q4 FY26 results · Jan–Mar 2026
Senores Pharmaceuticals reported revenue from operations of ₹175.19 crore (up 53.4% from Q4 FY25) and net profit of ₹36.67 crore (up 104.1% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 175.19 | 114.21 | +53.4% | 174.56 | +0.4% |
| Other income | 17.67 | 11.77 | +50.1% | 3.78 | +367.5% |
| Total income | 192.86 | 125.98 | +53.1% | 178.34 | +8.1% |
| Profit before tax | 47.40 | 20.68 | +129.2% | 44.60 | +6.3% |
| Net profit for the period | 36.67 | 17.97 | +104.1% | 33.58 | +9.2% |
| EPS, basic (₹) | 7.96 | 3.81 | +108.9% | 7.29 | +9.2% |
| Net margin (%) | 20.9 | 15.7 | 19.2 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 36.81 | 11.86 | +210.4% | 28.76 | +28.0% |
| Other income | 22.19 | 9.25 | +139.9% | 9.78 | +126.9% |
| Total income | 59.00 | 21.11 | +179.5% | 38.54 | +53.1% |
| Profit before tax | 12.69 | 2.90 | +337.6% | 3.52 | +260.5% |
| Net profit for the period | 8.48 | 2.02 | +319.8% | 2.65 | +220.0% |
| EPS, basic (₹) | 1.84 | 0.39 | +371.8% | 1.98 | −7.1% |
| Net margin (%) | 23.0 | 17.0 | 9.2 |
Consolidated
- Filed with BSE
- 14 May 2026, 19:30 IST
- Board meeting
- 14 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 May 2026, 19:30 IST
- Board meeting
- 14 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE